1Saltz L.Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor[J].J Clin Oncol,2004,22(6):1.
2Tabcrncro JM,Van Cutse mE,Sastre J,et al.An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil(5-FU)/ folinic acid(FA)(FOLFOX4) in the first-line treatment of patients with metastic colorectal cancer (CRC) expressing Epidemal Growth Factor Receptor (EGFR)[C].preliminary resuits.Proc Am Soc Oncol,2004,23:3512.
4Foon KA,Yang XD,Weiner LM,et al.Preclinical and clinical evaluations of ABX-EGF,a fully human anti-epidermal growth factor receptor antibody[J].Int J Radiat Oncol Biol Phys,2004,58:984.
5Daneshmand M,Parolin DA,Hirte HW,et al.A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients[J].Clin Cancer Res,2003,9:2457.
6Baselga J,Rischin D,Ranson M,et al.Phase Ⅰ safety pharmacokinetic and pharmacodynamic trial of ZD1839,a selective oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with five selected solid tumor types[J].J Clin Oncol,2002,20:4292.
7Goss G,Stewart D,Hirte H,et al.Initial results of part 2 of a phase Ⅰ/Ⅱ pharmacokinetics (PK),pharmacodynamic (PD) and biological activity study of ZD1839 (Iressa)[J].Proc Am Soc Clin Oncol,2002,21:[abstract 59].
8Fisher GA,Kuo T,Cho CD,et al.A phase Ⅱ study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer[J].J Clin Oncol,2004,22:3514.
9Townsley C,Major P,Siu LL,et al.Phase Ⅱ study of OSI-774 in patients with metastatic colorectal cancer[M].Gastrointest World Symp,2004:[abstract 222].
10Meyerhardt JA,Xhu A,Enzinger PC,et al.Phase Ⅱ study of capecitabine,oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC)[J].J Clin Oncol,2004,22:3580.
二级参考文献22
1Jose B. Why the epidermal growth factor receptor? The rational for cancer therapy. Oncologist,2002, (7 Suppl 4) :2-8.
2Caponigro F,Basile M,de Rosa V,et al. New drugs in cancer therapy,National Tumor Institute, Naples, 17-18 June 2004. Anticancer Drugs,2005,16(2) :211-221.
3Safavy A, Bonner JA, Waksal HW, et al. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.Bioconjug Chem,2003,14(2) :302-310.
4Govindan R. Cetuximab in advanced non-small cell lung cancer. Clin Cancer Res,2004,10( 12 Pt 2) :4241S-4244S.
5Prewett MC,Hooper AT, Bassi R,et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with ifinotecan against with human colorectal lumor xenografts. Clin Cancer Res,2002,8 ( 5 ) :994-1003.
7Janmaat ML,Giaccone G. The epidermal growth factor receptor pathway and its inhibition as amicancer therapy. Drugs Today (Bare) ,2003,39Suppl C :61-80.
9Johns TF,Stockert E, Ritter G, et al. Novel monnelonal antibody specific for the de2-Tepidermal growth factor receptor thay also recognizes the EGFR expressed in cells containing ampllfication of the EGFR gene. Int Cancer, 2002,98 ( 3 ) :398-408.
10Yang W, Barth RF, Ciesielski M J, et al. Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4. Clin Cancer Res,2005,11 ( 1 ) :341-350.
